The Manufacturers Life Insurance Company Has $191,000 Stock Position in Savara Inc (NASDAQ:SVRA)

The Manufacturers Life Insurance Company increased its holdings in shares of Savara Inc (NASDAQ:SVRA) by 9.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 44,956 shares of the company’s stock after buying an additional 3,706 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Savara were worth $191,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SVRA. California State Teachers Retirement System increased its holdings in shares of Savara by 411.0% in the first quarter. California State Teachers Retirement System now owns 75,986 shares of the company’s stock worth $378,000 after acquiring an additional 61,117 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Savara by 12.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company’s stock valued at $1,162,000 after purchasing an additional 32,142 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Savara by 967.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,008 shares of the company’s stock worth $177,000 after purchasing an additional 39,886 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares during the period. Finally, Victory Capital Management Inc. bought a new position in Savara in the second quarter valued at approximately $527,000. 87.93% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Savara news, CEO Matthew Pauls sold 54,702 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Joseph S. Mccracken acquired 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $2.95 per share, with a total value of $59,000.00. Following the transaction, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 5.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on SVRA. HC Wainwright lowered their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. Finally, Evercore ISI reissued an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Stock Performance

Shares of SVRA stock opened at $3.26 on Tuesday. The firm has a market cap of $559.48 million, a PE ratio of -7.58 and a beta of 0.92. Savara Inc has a 12 month low of $2.82 and a 12 month high of $5.70. The company’s fifty day simple moving average is $3.51 and its 200-day simple moving average is $4.01. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Equities research analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.